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Dynamic relocalization of NHERF1 mediates
chemotactic migration of ovarian cancer cells toward
lysophosphatidic acid stimulation
Yong-Seok Oh1, Kyun Heo2, Eung-Kyun Kim3, Jin-Hyeok Jang1, Sun Sik Bae4, Jong Bae Park2,5,
Yun Hee Kim2,5, Minseok Song6, Sang Ryong Kim7, Sung Ho Ryu8, In-Hoo Kim2,5 and Pann-Ghill Suh3
NHERF1/EBP50 (Na+/H+ exchanger regulating factor 1; Ezrin-binding phosphoprotein of 50 kDa) organizes stable protein
complexes beneath the apical membrane of polar epithelial cells. By contrast, in cancer cells without any ﬁxed polarity,
NHERF1 often localizes in the cytoplasm. The regulation of cytoplasmic NHERF1 and its role in cancer progression remain
unclear. In this study, we found that, upon lysophosphatidic acid (LPA) stimulation, cytoplasmic NHERF1 rapidly translocated to
the plasma membrane, and subsequently to cortical protrusion structures, of ovarian cancer cells. This movement depended on
direct binding of NHERF1 to C-terminally phosphorylated ERM proteins (cpERMs). Moreover, NHERF1 depletion downregulated
cpERMs and further impaired cpERM-dependent remodeling of the cell cortex, suggesting reciprocal regulation between these
proteins. The LPA-induced protein complex was highly enriched in migratory pseudopodia, whose formation was impaired by
overexpression of NHERF1 truncation mutants. Consistent with this, NHERF1 depletion in various types of cancer cells
abolished chemotactic cell migration toward a LPA gradient. Taken together, our ﬁndings suggest that the high dynamics of
cytosolic NHERF1 provide cancer cells with a means of controlling chemotactic migration. This capacity is likely to be essential
for ovarian cancer progression in tumor microenvironments containing LPA.
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INTRODUCTION
The epithelial–mesenchymal transition (EMT) is the process of
transdifferentiation of epithelial cells into motile mesenchymal
cells.1 During the EMT associated with tumor progression,
epithelial cells lose their intrinsic features, including cell-to-cell
junctions and apical–basal polarity, and undergo signiﬁcant
morphological changes to increase their potential for
dissemination, motility and invasion. This transition is
accompanied by signiﬁcant changes in expression, subcellular
localization and functions of multiple protein organizers that
deﬁne signaling pathways, cytoskeletal structure and lipid
composition at the plasma membrane. Many studies have
elucidated the key organizers that mediate the diversity,
polarity and dynamicity of the cortical structure of
cancer cells.
NHERF1 (Na+/H+ Exchanger Regulatory Factor), also
known as EBP50 (Ezrin-Binding Phosphoprotein 50) is a
member of the NHERF family.2–4 NHERF proteins are highly
expressed in several epithelial tissues and localize at the
apical plasma membrane of polar epithelia, which regulates
apical microvilli formation.5 An independent study identiﬁed
NHERF1 as a binding protein of Ezrin/Radixin/Moesin (ERM)
proteins,6 which play a crucial role in organizing membrane
domains through their ability to interact with transmembrane
proteins and the underlying cytoskeleton at the apical
membrane.7 Genetic ablation of NHERF1 or ERM results in
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malformation of apical microvilli, further supporting the idea
that the apical protein complex has a signiﬁcant function in
microvillar structure and regulation of polar epithelium.8,9
Furthermore, the levels of ERM proteins were signiﬁcantly
and speciﬁcally lower in the cortical brush border membranes
of kidney and small intestine epithelial cells of NHERF1
KO mice. In addition, NHERF1 depletion in cultured cells
signiﬁcantly reduces, but does not eliminate, the microvilli
structure on the cell cortex,10,11 which is reversed by the
expression of an NHERF1 construct.12
Like other scaffolding proteins, NHERF proteins contain
multiple protein interaction modules, including two N-term-
inal tandem PDZ domains and a C-terminal ERM-binding
domain.6,13,14 The PDZ domains interact with a wide variety of
transmembrane proteins, including growth factor receptors,
G-protein-coupled receptors, ion channels, cell adhesion mole-
cules and cytosolic signaling molecules such as phospholipase
C, protein kinases and ERM family proteins.15–18 NHERF1
serves as a molecular scaffold that mediates the formation of a
functional unit by bringing multiple binding partners together
into a protein complex. Through these molecular interactions,
NHERF proteins play prominent roles as regulators of trans-
membrane signal transduction, cytoskeletal reorganization,
receptor trafﬁcking and phosphoinositide metabolism.18–20
Lysophosphatidic acid (LPA) is involved in biological
responses such as rapid actin rearrangement, stimulation of cell
proliferation, suppression of apoptosis and induction of tumor
cell invasion.21,22 LPA induces these responses by binding to
members of the LPA receptor (LPAR) family.21,23 Several lines
of evidence have implicated the LPA/LPAR axis in the pathology
of human cancers. Since the initial identiﬁcation of oleoyl-LPA
as the crucial molecule in fetal calf serum (FCS) that promotes
rat hepatoma cell invasion,24 LPA has also been shown to be the
bioactive lipid component of ovarian cancer activating factor
(OCAF), which stimulates ovarian cancer cells.25 Notably, the
level of LPA is signiﬁcantly elevated in ascites and sera of most
patients with ovarian cancer with poor prognostic
outcome.22,25–28 In addition, LPA is associated with the EMT:
LPARs are highly upregulated during EMT, rendering post-EMT
cells more responsive to LPA.29 Furthermore, LPA promotes the
migratory and invasive properties of cancer cells,21,22 eventually
resulting in metastasis and poor clinical outcome.22,30,31
NHERF proteins are closely associated with tumor
development. Initially, NHERF1 was proposed to be a tumor
suppressor, in part based on its reduced expression32 and
allelic loss33 in various tumor types. However, other studies
argued that NHERF1 contributes to cancer progression, based
on analyses of large numbers of tumor samples34–36 and
in vitro models using tumor cell lines.37 Despite persistent
controversy regarding NHERF1 expression in cancer cells,
consensus has emerged regarding the altered subcellular
distribution of NHERF1 in the tumor mass and cultured
cancer cell lines.32,38–41 Speciﬁcally, an abnormal transition of
NHERF1 localization from the apical membrane of normal
epithelium to the cytoplasm, or even the nucleus, has been
observed during the EMT in various kinds of tumors. This
relocalization is associated with cancer progression, metastatic
potential, poor prognosis and estrogen responsiveness,
especially in carcinomas. However, despite mounting evidence
regarding the pathogenic role of cytosolic NHERF1, little is
known about how cytosolic NHERF1 in post-EMT cells
behaves in response to the extracellular microenvironment.
In this study, we investigated the regulation of cytosolic
NHERF1 in response to LPA stimulation and its contribution




Chemical reagents. Lysophosphatidic acid (1-oleoyl-2-hydroxy-sn-
glycerol-3-phosphate) was purchased from Enzo Life Sciences
(Farmingdale, NY, USA). Synthetic siRNA duplexes and Lipofectamine
2000 were from Dharmacon (Lafayette, CO, USA) and Life Technol-
ogies (Carsbad, CA, USA), respectively. Cell culture dishes and plates
were obtained from BD Bioscience (San Jose, CA, USA). The 96-well-
modiﬁed Boyden chambers (polycarbonate membranes) were from
NeuroProbe (Cabin John, MD, USA); two different pore sizes were
used, 8 and 5 μm for the Transwell migration assay and pseudopodia
formation assay, respectively. The serum and medium were obtained
from Life Technologies, and other chemicals were purchased from
Sigma-Aldrich (St Louis, MO, USA) in extra-pure or higher grade.
Antibodies. Rabbit polyclonal α-NHERF1 and α-NHERF2 Ab were
generated by immunization of the 6xHis-tagged C-terminal fragment
of NHERF1 or − 2 (CT: aa 261–351) as described previously.18 α-ERM
(catalog no. #3142), α-cpERM (catalog no. #3141), α-pGSKα/β (catalog
no. #9331), α-pERK1/2 (catalog no. #3179) and α-pAKT (catalog no.
#4060) antibodies were obtained from Cell Signaling Technology
(Danvera, MA, USA). α-VSVG antibody was from Sigma-Aldrich.
Plasmid construction
Various plasmid constructs were generated by PCR methods.
Full-length cDNAs were PCR ampliﬁed using primer pairs for
hNHERF1 with appropriate overhang for enzyme cleavage. The PCR
products for hNHERF1 WT (aa 1–351), and its deletion fragments
(ΔCT: aa 1–260, CT: aa 261–351), were digested with BamHI/XhoI and
ligated into pEGFP-C1 or pET30a (+). For cloning into pCMV2-FLAG,
PCR products were digested with BglII/XhoI and ligated into pCMV2-
FLAG digested with BglII/SalI. GFP-tagged NHERF1-WT was ampliﬁed
from pEGFP-C1-hNHERF1-WT, and the amplicons were digested with
NotI/ClaI and cloned into pAvCMV3 to generate recombinant
adenovirus. VSVG epitope-tagged Ezrin WT and its T567A mutant in
vector pCB6+ were generous gifts from Dr Monique Arpin. Each
cDNA was ampliﬁed with NotI/ClaI restriction site overhangs and
cloned into pAvCMV3. All mutations were veriﬁed by automated
sequencing.
Cell culture and transfection
OVCAR-3, SK-OV-3 and MDA-MB-231 cells were from the American
Type Culture Collection (ATCC, Manassas, VA, USA). These cell lines
were maintained in Dulbecco’s modiﬁed Eagle medium (DMEM)
supplemented with penicillin (50 units per ml), streptomycin (50 units
per ml) and 10% fetal bovine serum (FBS, Life Technologies) at 37 °C
in 95% air/5% CO2. HIO-80, the immortalized human normal
ovarian surface epithelial cell line, was a kind gift from Dr Andrew
Godwin at the Fox Chase Cancer Center, Philadelphia, PA; these cells
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were cultured in medium 199 and MCDB 105 (1:1) supplemented
with 15% FBS, 0.25 U ml− 1 insulin, and 2 mM L-glutamine. For
transient transfection, cells were plated into 100 mm dishes and
transfected with either siRNA duplexes or plasmid constructs using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
Agonist treatment and cell harvest
Cells were seeded into six-well plates at a density of 1.5 × 106 cells per
well. After serum deprivation for 24 h, the cells were treated with LPA
as indicated. Each plate was then washed twice with cold phosphate-
buffered saline (PBS), and the cells were lysed in 150 μl of cold lysis
buffer containing 50 mM HEPES, 150 mM NaCl, 50 mM NaF, 1 mM
EDTA/EGTA, 1 mM Na3VO4 and 10% v/v glycerol. Lysates were
mildly sonicated and cleared by centrifugation at 4 °C. Protein
concentration was determined by BCA assay (Thermo Fisher
Scientiﬁc, Waltham, MA, USA).
Knockdown by siRNA transfection
SiRNA duplexes targeting NHERF1 (451–469) and NHERF2
(862–880) were synthesized by GE Dharmacon as described in a
previous study.18 Pre-synthesized control siRNA duplexes (Luciferase
GL3 Duplex) were also purchased and used as controls. Cultured cells
were transfected with 20 nM oligonucleotide using Oligofectamine
(Thermo Fisher Scientiﬁc) under serum-free conditions. Four hours
after transfection, cells were washed and supplemented with fresh
media containing 10% FBS. Cells were incubated for 72 h before use
in experiments.
Recombinant adenovirus production and infection
Recombinant adenovirus expressing GFP-tagged NHERF1 or VSVG-
tagged Ezrin (WT or T567A mutant) was generated and ampliﬁed in
HEK-293T cells and puriﬁed by CsCl gradient centrifugation accord-
ing to the standard protocol.42 OVCAR-3 cells grown to conﬂuence in
six-well plates were infected at a multiplicity of infection (MOI) of
10 for 4 h in serum-containing media. In parallel, monolayers were
infected with adenovirus containing empty shuttle vector, as a negative
control for any nonspeciﬁc effect of viral infection on cell viability.
Immunoprecipitation and western blot analysis
Cells were lysed in the lysis buffer and the lysates were allowed to
immunoreact with the appropriate antibodies or α-FLAG afﬁnity
resin. Immune complexes were collected by centrifugation at 1000 g,
and then washed four times with 1 ml of lysis buffer. The resultant
precipitates were subjected to SDS-polyacrylamide gel electrophoresis
and analyzed by western blot analysis.
Prior to SDS-polyacrylamide gel electrophoresis, all samples were
boiled in Laemmli buffer and separated on 6–16% gels according to
the standard protocols. Resolved proteins were transferred to nitro-
cellulose membranes. Membranes were blocked for 1 h in T-TBS
buffer containing 10 mM Tris-HCl (pH 7.6), 150 mM NaCl, 0.1%
Tween-20 and 5% non-fat milk. Western analyses of OVCAR-3 and
MDA-MB-231 cell lysates were probed with antibodies as indicated in
each ﬁgure. Blots were developed using enhanced chemiluminescence
solution (ECL, GE Healthcare; Little Chalfont, Buckinghamshire, UK).
Immunocytochemistry
OVCAR-3 cells were seeded onto cover glasses coated with 10 μg ml− 1
collagen type I (Sigma-Aldrich). Cells were transfected with either
siRNA duplexes or cDNA constructs, and then serum-deprived for
24 h in DMEM supplemented with 0.1% fatty acid-free BSA.
The serum-starved cells were treated with LPA pre-diluted in 0.1%
BSA as indicated in ﬁgure legends. Cells were washed with PBS and
ﬁxed for 20 min at room temperature with 3.7% paraformaldehyde in
PBS. Fixed cells were rinsed with TBS (50 mM Tris-HCl (pH 7.4),
150 mM NaCl) and incubated with the permeabilization buffer
(PBS supplemented with 0.2% Triton X-100) for 10 min. Cells were
rinsed three times for 5 min each with TBS, and then incubated with
blocking solution (10% horse serum, 1% BSA, and 0.02% NaN3 in
PBS) for 1 h at room temperature. The cells were then stained with
α-ERM, α-cpERM and α-VSVG antibodies, and nuclear DNA was
stained with Hoechst 33342. Images were captured with simultaneous
recording of multiple channels using confocal microscopy (LSM510,
Carl Zeiss, Oberkochen, German). Images were digitized using Zeiss
imaging software and compiled using Adobe Photoshop Software
(Adobe Systems, San Jose, CA, USA).
Cell migration assays using modiﬁed Boyden chambers
Cell migration assays were performed as previously described43
with minor modiﬁcations. Brieﬂy, cell migration assays were
performed using modiﬁed Boyden chambers (tissue culture-treated,
5.7 mm diameter, 8 μm pores, ChemoTX; NeuroProbe; Gaithersburg,
MD, USA) containing polycarbonate membranes. The underside of
the membrane of the upper chamber was coated with 10 μg ml− 1
collagen type I (Thermo Fisher Scientiﬁc) overnight at 4 °C, rinsed
once with 1× PBS, and then placed into the lower chamber
containing 300 μl of migration buffer (serum-free basal medium, with
0.1% fatty acid-free BSA). The cells were removed from culture dishes
with diluted trypsin/EDTA (PBS, 0.01% trypsin, and 5 mM EDTA),
washed twice with migration buffer, and then resuspended in migration
buffer (5×105 cells per ml). Next, 2.5 × 104 cells were added to the top
of each migration chamber and allowed to migrate to the underside of
the top chamber for 3 h. Non-migratory cells on the upper membrane
surface were removed with a cotton swab, and the migratory cells
attached to the bottom surface of the membrane were ﬁxed in ﬁxation
buffer (PBS containing 2% paraformaldehyde), incubated with 0.2%
Triton X-100 solution for 10 min at room temperature, and then
stained with Hoechst 33342 diluted in PBS. After three washes with
PBS, the membrane was excised from the frame and mounted onto
the slide glasses. The numbers of migratory cells per membrane were
counted with an inverted ﬂuorescence microscope using a × 40
objective. Each determination represents the average of three indivi-
dual wells, and error bars represent s.d.
Immunostaining of the pseudopodia of the migratory cells
Pseudopodia were generated at the beginning of the migration process,
prior to cell body passage through the porous membrane of the
ChemoTX chamber. To allow efﬁcient formation of protruding
pseudopodia, the cells were detached from the culture dish,
resuspended in migration buffer, mounted onto the porous transpar-
ent membrane of a ChemoTX chamber (5 μm pore size) at a density
of 1× 104 cells per well, and incubated for 1 h (instead of 3 h as in the
standard migration assay). The membrane was washed brieﬂy with
ice-cold 1×PBS containing phosphatase inhibitors. The cells were
then immediately ﬁxed with 2% PFA solution and permeabilized for
10 min at room temperature with 0.2% Triton X-100 solution. After
soaking in blocking solution for 1 h, the membrane was incubated
overnight with α-cpERM antibody diluted in blocking solution. For
nuclear staining, the membrane was incubated for 30 min at room
temperature with 1 μg ml− 1 propidium iodide along with 10 μg ml− 1
RNase A. After the ﬁnal wash, the membrane was excised from the
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frame, mounted on slide glass, and covered with a cover glass. Using
confocal microscopy (LSM510-Meta, Zeiss), images of the cell body
and pseudopodia were captured in the same region with different
planes of focus, but with constant settings including contrast and gain.
Statistical procedure
All quantitative data are presented as mean ± s.e.m. Two group
comparisons were done by two-tailed, unpaired Student’s t-test.
Multiple group comparisons were assessed using a one-way or
two-way ANOVA, followed by the post hoc Bonferroni test,
respectively, when signiﬁcant main effects or interactions were
detected. Statistical signiﬁcance was set at Po0.05. All comparisons
were performed with Prism Software (GraphPad Software, SanDiego,
CA, USA).
RESULTS
NHERF1 translocates from cytosol to surface protrusions in
response to LPA stimulation
Although NHERF1 has been observed in cortical actin-rich
structures such as membrane rufﬂes, ﬁlopodia and microvilli, it
remained unknown whether the subcellular localization of
NHERF1 is dynamically regulated by extracellular stimuli.
In this study, we examined the effect of LPA stimulation
on NHERF1 localization in ascites-derived OVCAR-3 ovarian
cancer cells. In serum-deprived cells, NHERF1 localized
diffusely at the cytosol, whereas LPA stimulation induced rapid
NHERF1 translocation to the plasma membrane at the cell
margin (Figure 1a). Interestingly, over time following LPA
stimulation, OVCAR-3 cells underwent marked morphological
changes, generating protruding structures on the cell surface.
These protrusions were distributed throughout the plasma
membrane of LPA-exposed cells (Figure 1b). NHERF1, which
translocated from cytosol to the cell margin, was targeted to
these structures. This observation highlights the dynamic
relocalization of cytosolic NHERF1 in cancer cells without
ﬁxed polarity, in stark contrast to its static apical localization in
polar epithelial cells.8
LPA-induced NHERF1 translocation is mediated by direct
interaction with cpERM proteins at the cell margin
Based on the established interaction between NHERF1 and
active ERM proteins at the apical microvilli of polar
epithelia,5,8,19,44 we postulated that NHERF1 translocation in
cancer cells might depend on a conserved interaction with
active ERM proteins. Interestingly, LPA stimulation has been
shown to induce ERM phosphorylation in Swiss 3T3 ﬁbroblast
cells.45 To test this idea, we ﬁrst investigated whether ERM
proteins in OVCAR-3 cells are phosphorylated by LPA
stimulation, an established marker of ERM activation.46
LPA stimulation of OVCAR-3 cells resulted in rapid
ERM phosphorylation at the conserved threonine residue
in a dose-dependent manner (Figure 2a). In addition,
co-immunoprecipitation of LPA-stimulated OVCAR-3 cell
lysates revealed that NHERF1 interacts with cpERM proteins
(Figure 2b), conﬁrming the direct interaction between
NHERF1 and cpERM proteins.6 The cpERM–NHERF1 inter-
action occurs only after LPA stimulation, which is completely
abolished by the deletion of the C-terminal region containing
the ERM-binding domain (NHERF1-ΔCT).
Next, we examined the signiﬁcance of the NHERF1–ERM
interaction in the translocation event. Wild-type NHERF1
(GFP-NHERF1 WT) translocated rapidly from the cytosol to
the cell margin where cpERM proteins are generated, and
subsequently to surface protrusions along with cpERM proteins
(Figure 2c). After LPA stimulation, the localizations of the two
proteins at the plasma membrane completely overlapped,
especially at the cortical structure (Figure 2c). More impor-
tantly, NHERF1 translocation was completely abrogated by a
C-terminal deletion mutation in NHERF1 (NHERF1-ΔCT)
that resulted in loss of the ERM interaction (Figure 2d),
demonstrating that the interaction with ERM proteins is
essential for this translocation event. Consistent with this,
high-magniﬁcation images revealed that NHERF1 co-localized
with cpERM proteins at heavy protrusions in LPA-stimulated
cells (Figure 2e). To conﬁrm the signiﬁcance of ERM
phosphorylation in NHERF1 localization, we examined the
subcellular localization of all ERM proteins using another ERM
antibody that preferentially recognizes non-phospho-ERM
proteins. Even in LPA-stimulated cells, non-phosphorylated
ERM proteins exist in a subcortical layer beneath the plasma
membrane, presumably through PIP2 interaction as the
dormant forms (Figure 2f, arrowheads).46 It is obvious that
NHERF1 (green, arrow) did not signiﬁcantly overlap with the
dormant ERM proteins (red, arrowheads), suggesting that
NHERF1 and cpERM proteins engage in a speciﬁc interaction
at the cortical structure. These results indicated that
LPA-triggered ERM phosphorylation is responsible for rapid
translocation of NHERF1 to the cortical structure.
NHERF1 potentiates ERM phosphorylation in
LPA-stimulated cells by stabilizing cpERM proteins
We next attempted to determine the potential role of
NHERF1–cpERM interaction in ERM regulation at the plasma
membrane. To deplete NHERF1 proteins, we transfected
NHERF1-speciﬁc siRNA duplex into OVCAR-3 cells
(Figure 3a–d). We then investigated whether the absence of
NHERF1 inﬂuences the phosphorylation status of ERM
proteins in LPA-stimulated cells. NHERF1 depletion
signiﬁcantly decreased the LPA-induced level of ERM
phosphorylation at all treatment times examined (Figure 3a).
This inhibitory effect of NHERF1 depletion was reproduced in
cells stimulated with various concentrations of LPA, whereas
NHERF1 depletion had little effect on other LPA-triggered
signal events such as phosphorylation of AKT, GSKα/β and
ERK, suggesting that NHERF1 plays a speciﬁc role in the
regulation of ERM proteins (Figure 3b).
Conversely, we examined the effect of NHERF1 over-
expression on the cpERM level following LPA stimulation.
Despite the similarity in their tissue origin, HIO-80 cells
(human immortalized ovary epithelial cell line) express a much
lower level of NHERF1 than ovarian carcinoma cell lines
(OVCAR-3 and SK-OV-3), without any signiﬁcant difference
in the level of ERM proteins (Figure 3c). Overexpression of
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Figure 1 NHERF1 translocates from cytosol to plasma membrane upon LPA stimulation, and then to surface protrusions. (a) Time-lapse
imaging of LPA-induced NHERF1 translocation. OVCAR-3 cells were plated onto type I-coated glass-bottom dishes and transfected with
GFP-tagged NHERF1 construct. After serum deprivation for 24 h, the cells were incubated in Phenol Red-free DMEM and stabilized for
20 min. After adjusting the plane of focus near the bottom region close to the glass surface, time-lapse scanning was performed at 2 min
intervals after 1 μM LPA stimulation. Scale bar, 20 μm. Relative intensities of GFP ﬂuorescence are shown along the broken line of the long
arrow (yellow) overlaid on each image, using the line scan tool of Image J software. The relative distribution of GFP-NHERF1 at each time
point is plotted in the graph in the right lower corner. (b) High-resolution image of NHERF1 translocation from cytosol to surface
protrusions in response to LPA stimulation. OVCAR-3 cells expressing GFP-NHERF1 were stimulated with 1 μM LPA, ﬁxed, and observed by
confocal microscopy. The focuses of the confocal imaging are adjusted to the top and the bottom region sequentially, as indicated. Scale
bar,20 μm. Relative intensities of GFP ﬂuorescence intensities are shown along the broken line of the long arrow (yellow) overlaid on each
image. The relative distribution of GFP-NHERF1 is plotted in the graph immediately below each image.
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GFP-tagged NHERF1 over the endogenous level signiﬁcantly
increased the LPA-induced level of cpERM proteins,
whereas C-terminal deletion of NHERF1 abolished this effect
completely, further conﬁrming the importance of the direct
interaction of NHERF1 with cpERM proteins for this
regulation. Consistent with this, the effect of NHERF1 over-
expression is selective for cpERM proteins and does not
inﬂuence other phosphorylation events, as demonstrated
for the pERK pathway (Figure 3d and e). These results
demonstrate that, in response to LPA stimulation, NHERF1
is recruited to cpERM proteins, which stabilize and/or
potentiate its activation status.
The NHERF1–cpERM complex is required for LPA-induced
reorganization of the cell cortex
ERM proteins were initially identiﬁed as enriched in various
membrane structures such as microvilli, membrane rufﬂes and
ﬁlopodia.5,19 In these structures, they play an essential role in
actin cytoskeleton reorganization, assembly of focal adhesion
complexes, and membrane dynamics by linking membrane
proteins to the cortical actin cytoskeleton. Based on our
observation of reciprocal regulation between NHERF1 and
cpERM proteins, we hypothesized that the NHERF1–cpERM
complex mediates LPA-induced dynamic membrane morpho-
genesis of OVCAR-3 cells. To test this idea, we overexpressed a
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phosphorylation-defective T567A mutant of Ezrin, which
has a dominant-negative effect on endogenous ERM proteins.
Overexpressed WT Ezrin was targeted to membrane
protrusions with nearly the same localization pattern as cpERM
proteins, whereas Ezrin-T567A was not (Figure 4a). Moreover,
Ezrin-T567A overexpression markedly attenuated proper
targeting of endogenous cpERM proteins to the cortical
membrane and interfered with membrane protrusion
formation elicited by LPA. This result indicated that
cpERM proteins play pivotal roles in LPA-induced membrane
reorganization/remodeling.
We next examined the effect of NHERF1 depletion on
LPA-induced reorganization of the cell cortex. CpERM
proteins in control cells were targeted to surface protrusion
structures generated in either the membrane surface of the top
region or the cell margin of the bottom region. By contrast,
in NHERF1-deﬁcient cells, cpERM proteins were present
at markedly lower levels, and the cells were impaired in
generation of surface protrusions (Figure 4b). This effect was
marginal in NHERF2-deﬁcient cells, suggesting that NHERF1
makes a major contribution to cpERM regulation in OVCAR-3
cells. Quantitative analysis of the cells with heavy protrusions
revealed that NHERF1 knockdown caused marked reduction
in LPA-induced formation of surface protrusion structures
(Figure 4c and d). These results strongly support the functional
signiﬁcance of NHERF1–cpERM protein complexes in the
regulation of dynamic membrane morphogenesis.
NHERF1–cpERM complexes are enriched in pseudopodia of
OVCAR-3 cells migrating toward a LPA gradient
During migration, tumor cells form a distinct plasma
membrane domain, the pseudopod, whose generation and
stabilization determines the directionality of cell movement.47
The rapid movement of cells requires local dynamics in the
cytoskeleton and membrane; consequently, cell motility
requires a supply of the appropriate molecular machinery at
the site of pseudopodial extension. In light of the
LPA-dependent regulation of the NHERF1–cpERM complex
and its crucial role in membrane morphogenesis, we explored
the possibility that the NHERF1–cpERM complex is targeted to
the pseudopod, where dynamic remodeling in membrane
morphology happens toward chemotactic stimulus. To
visualize NHERF1 and cpERM proteins in the pseudopodia,
we immunostained cells that were ﬁxed during migration
through a transparent porous membrane. In these experiments,
OVCAR-3 cells were mounted on the upper side of the porous
membrane, and the reservoir on the lower side was ﬁlled with
migration buffer containing 1 μM LPA; the cells were then
allowed to extend pseudopodia through the membrane toward
the LPA stimulus (Figure 5a, left panel). We modiﬁed our
chemotaxis assay by decreasing both the pore size of the
membrane (5 μm) and the incubation time (1 h); these
conditions allow pseudopodial projection, but not migration
of the cell body (Figure 5a, left panel). In this model, cpERM
proteins were highly enriched in pseudopodia only when LPA
was present in the lower chamber (Figure 5aa–c). We further
validated the pseudopodial localization of cpERM proteins at
the underside of the porous membrane by nuclear staining of
the cell body on the upper side (Figure 5ab), as well as by
removing any residual cells on the upper side following
chemotaxis (Figure 5ac). At higher magniﬁcation, we observed
that cpERM proteins were targeted to protrusive structures of
the pseudopodia (Figure 5ba and -b), but to a much lesser
extent to the cell membrane near the cell body, suggesting
uneven activation of ERM proteins toward the LPA gradient.
Notably, this cpERM localization was overlapped with that of
NHERF1 not only in the pseudopodia, but also in their
protrusion structures (Figure 5c-b and -c), but not with
control GFP protein (Figure 5ca). Collectively, these results
indicated that NHERF1 translocates to sites on the membrane
where cpERM proteins are generated in the direction of the
LPA gradient, leading to pseudopodial enrichment of the
NHERF1–cpERM protein complex, followed by local mem-
brane morphogenesis involved in chemotactic cell migration.
Figure 2 NHERF1 translocation depends on the molecular interaction with ERM proteins phosphorylated at the C terminus (cpERMs) in
response to LPA stimulation. (a) Lysophosphatidic acid (LPA)-induced ERM phosphorylation. OVCAR-3 cells were serum-deprived for 24 h,
and then stimulated with LPA in various concentrations indicated. The levels of cpERM and the total amounts of ERM and NHERF1 were
determined by western blotting using antibodies speciﬁc for cpERM, ERM proteins (ERM) or NHERF as indicated. (b) LPA-induced
interaction between NHERF1 and cpERM proteins. FLAG-tagged NHERF1 wild-type (FLAG-NHERF1 WT) and a C-terminally deleted form
(FLAG-NHERF1 ΔCT) were transfected into OVCAR-3 cells. After serum deprivation for 24 h, cells were stimulated with 1 μM LPA and
lysed. FLAG-tagged NHERF1 was immunoprecipitated with anti-FLAG afﬁnity resin. Co-immunoprecipitation of cpERM with FLAG-NHERF1
was monitored by western blotting using anti-cpERM antibody. (c, d) CpERM-dependent translocation of NHERF1. OVCAR-3 cells on
collagen-coated cover glass were transfected with GFP-tagged NHERF1 constructs, either wild-type (NHERF1-WT) (c) or a mutant lacking
the C-terminal ERM-binding region (NHERF1-ΔCT) (d). Serum-deprived cells were treated with vehicle or 1 μM LPA for the indicated times.
After ﬁxation and permeabilization, the cells were immunolabeled with anti-cpERM antibody. Time-dependent localization of both cpERM
proteins and NHERF1 was examined under a confocal microscope with constant settings. Upon LPA stimulation, the cpERM level was
markedly elevated, and cpERM co-localized at the cell margin and in surface protrusions with wild-type NHERF1 (c, arrows), but not with
NHERF1-ΔCT (d, arrowheads). Scale bars, 20 μm. Relative ﬂuorescence intensities are proﬁled along the line of the long arrow (blue)
overlaid on each image, using the line scan tool of Image J software. The relative distributions of NHERF1 and cpERM proteins along the
line (blue) are plotted in the graph (right panel of each image). (e, f) cpERM-speciﬁc co-localization of NHERF1. OVCAR-3 cells expressing
EGFP-tagged NHERF1 were prepared as described above and immunostained with antibodies speciﬁc for C-terminal phosphorylated ERM
proteins (e) or an anti-ERM antibody that preferentially binds unphosphorylated ERM proteins (f). Lower panels show higher magniﬁcations
of the yellow boxed regions of the upper panels. NHERF1 co-localized at protrusion structures with cpERM (e, arrows), but not with total
ERM proteins (f, arrowheads). These results are representative of three independent experiments. Scale bars, 20 μm.
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NHERF1 plays a pivotal role in LPA-induced cell migration
of gynecological carcinoma cells
Based on observation of dynamic targeting of the NHERF1–
cpERM complex to the pseudopodia, we postulated that this
complex is required for the directional migration of tumor cells
toward a LPA gradient. First, we examined the effect of
NHERF1 truncation mutant expression on pseudopodia
formation (Figure 6a and b). In contrast to full-length
NHERF1 (NHERF1-WT, left panel), the C-terminal fragment
(NHERF1-CT, right panel) completely abrogated pseudopodia
Figure 3 NHERF1 potentiates ERM phosphorylation in LPA-stimulated cells. (a, b) Effect of NHERF1 depletion on LPA-induced ERM
phosphorylation. OVCAR-3 cells were transfected with siRNA duplexes speciﬁc for NHERF1, NHERF2 or control siRNA (luciferase GL3).
One day after transfection, the cells were re-plated onto collagen-coated culture dishes. One day later, the cells were serum-deprived for
24 h and treated with 1 μM LPA for various times (a) or with various doses of LPA for 10 min (b) as indicated. LPA-induced levels of
cpERM, pAKT, pSGKα/β and pERK in the cell lysates were determined by western blot analysis with the indicated phospho-speciﬁc
antibodies (a, b). The amounts of total ERM proteins, NHERF1 and NHERF2 in the same cell lysates were also determined using the
appropriate cognate antibodies (a). Black arrows indicate cognate target proteins, and the blue arrowhead indicates nonspeciﬁc bands in
the western blot image (a). These results are representative of three independent experiments. The relative intensity of each immunoblot
image is shown in the graph at the right side. Data represent mean ± s.e.m. *Po0.05 and **Po0.01, t-test. (c) Expression levels of
NHERF1 and ERM proteins in ovarian cell lines derived from either normal or cancerous epithelium. NHERF1 and ERM protein levels in
the cell lysates of HIO-80, SK-OV-3 and OVCAR-3 are shown together with the GAPDH level as an input control. (d, e) Potentiation of
ERM phosphorylation by overexpression of NHERF1. HIO-80 cells were transfected with GFP-NHERF1 (WT) or its C-terminally deleted
form (ΔCT). Immunoblot analyses with anti-GFP and anti-NHERF1 antibody were performed to determine the expression level of each
NHERF1 construct and the degree of overexpression of GFP-NHERF1 relative to the endogenous NHERF1 level, respectively (d).
LPA-induced levels of cpERM and pERK, as well as total ERM level, were determined as described above. All of these results represent
three independent experiments.
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Figure 4 NHERF1 is required for cpERM-dependent dynamic reorganization of the cell cortex. (a) The role of ERM phosphorylation in
LPA-induced remodeling of the cell cortex. OVCAR-3 cells were transfected with VSVG-tagged Ezrin constructs, including wild-type Ezrin
and the phosphorylation-defective mutant (Ezrin-T567A). The transfected cells were treated with 1 μM LPA for 10 min. The ﬁxed cells were
immunostained with α-VSVG epitope and α-cpERM antibody, and then observed by confocal microscopy with the focus adjusted to
either the top or the bottom side of the cells. CpERM proteins co-localized with VSVG-tagged Ezrin wild-type (arrows), but not with its
dominant-negative mutant Ezrin-T567A (arrowheads). All images are from a single experiment, which was representative of three
independent experiments. Scale bars, 20 μm. (b–d) Effect of NHERF1 depletion on cpERM-dependent reorganization of the cell cortex.
OVCAR-3 cells were transfected with siRNA duplexes speciﬁc for NHERF1 or −2. The transfected cells were re-plated onto collagen-
coated glass coverslips and serum-deprived for 24 h prior to 1 μM LPA treatment for 10 min. Generation and subcellular localization of
cpERM protein was visualized by immunostaining with anti-cpERM antibody (b). Images were acquired by confocal microscopy with the
focus adjusted to either the top or the bottom side of the cells. CpERM localization is indicated at surface protrusions (arrows) and at the
cell margin (arrowheads). All images are from a single experiment that was representative of three independent experiments. Scale bars,
20 μm. Speciﬁc gene silencing of NHERF1 and NHERF2 with transfection with isoform-speciﬁc siRNAs (c). Protein levels of NHERF1 and
NHERF2 were determined using speciﬁc antibodies. Representative western blot images for each group and NHERF isoform are shown.
Proportion of LPA-stimulated cells with heavy protrusions (d). Images in each slide were captured in 5–7 randomly selected high-power
ﬁelds (HPF, ×20 objective) with constant settings. Number of total cells and cells with heavy protrusions deﬁned as those with typical
protrusive structures covering the cell edge of the bottom region by more than 1/4. Representative images of the cells with or without
typical heavy protrusions are as shown in c. The results from each slide show the percentage of the cells with heavy protrusions. Each bar
represents the mean± s.e.m. from three independent experiments. All data represent mean± s.e.m. Pair-wise post hoc test, #Po0.001,
*Po0.05, NS, non-signiﬁcant.
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formation in the majority of the transfected cells, suggesting
that its potent dominant-negative activity was mediated
via its competitive interference with the NHERF1–cpERM
interaction. In addition, a C-terminal deletion of NHERF1
(NHERF1-ΔCT, middle panel) inhibited pseudopodia
formation, but much less strongly than NHERF1-CT.
Nonetheless, pseudopodia formation was signiﬁcantly attenu-
ated in cells expressing NHERF1-ΔCT at high levels (arrows),
but not in the cells with low or undetectable expression (yellow
arrowheads). Importantly, both NHERF1 mutants exerted the
same inhibitory effects on pseudopodia formation, suggesting
that full-length NHERF1-dependent molecular scaffolding
established by both the two N-terminal PDZ domains and
the C-terminal cpERM-binding region may be required for
pseudopodia formation for the migratory process.
Based on our observation of LPA-induced assembly
of the NHERF1–cpERM complex at polar pseudopodia,
we investigated whether this molecular complex mediates the
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chemotactic migration of those cancer cells toward LPA. First,
we observed that the phosphorylation-defective ezrin mutant
(Ezrin-T567A) blocked LPA-induced migration of OVCAR-3
cells (Supplementary Figure 1A–C). Consistent with this, in
gynecological cancer cell lines such as OVCAR-3, SK-OV-3,
and MDA-MB-231, NHERF1 depletion resulted in the
almost complete loss of migration toward the LPA gradient
(Figure 6c–e). Collectively, those results suggested that cytosolic
NHERF1 plays a signiﬁcant role in directional migration of
gynecological cancer cells in response to LPA.
DISCUSSION
The classical apical scaffolding protein NHERF1 was previously
shown to relocalize to the cytoplasm in post-EMT cancer cells,
but its role in tumor progression remained unclear. Here we
showed that cytosolic NHERF1 dynamically translocates to the
plasma membrane upon LPA stimulation of ascites-derived
OVCAR-3 ovarian cancer cells. Translocation of NHERF1 is
mediated through molecular interaction with cpERMs at the
plasma membrane of LPA-stimulated cells (Figure 7a and b).
cpERM and NHERF1 are engaged in reciprocal regulation, and
form a molecular complex that plays a signiﬁcant role in
dynamic remodeling of the cell cortex (Figure 7c and d).
In vitro chemotactic migration assays revealed that the
NHERF1–cpERM complex is highly enriched in a frontal
pseudopodial structure extending toward the LPA gradient
that is essential for cancer cell migration (Figure 7e). Our
results suggest that local translocation of cytoplasmic NHERF1
provides post-EMT cancer cells with a means to freely move
toward a chemotactic stimulus (in this case, LPA). Taken
together, these results suggested that NHERF1 dynamics play a
signiﬁcant role in controlling cancer cell behavior in the tumor
microenvironment, and likely promote ovarian cancer
progression.
Reciprocal regulation of NHERF1 and cpERM proteins
We showed that NHERF1 translocation depends on
LPA-induced ERM phosphorylation and subsequent interac-
tion via the NHERF1 C terminus underneath the plasma
membrane, validating the important role of ERM proteins in
NHERF1 regulation in cancer cells, as in normal epithelial cells.
In dormant monomer of the ERM family proteins, N-ERMAD
(ERM-association domains) for binding site of membrane-
associated proteins binds very tightly to its C-terminal
F-actin-binding site, C-ERMAD in the closed conformation.7
Activation of ERM proteins to unmask their binding sites
involves dissociation of the intramolecular N-/C-ERMAD
interaction, which is achieved by two sequential steps:
PIP2 binding to the N-terminal domains, and subsequent
phosphorylation of a C-terminal threonine residue by multiple
cellular kinases.3 It is noteworthy that, even before extracellular
stimulation, most non-phosphorylated ERM proteins localize
throughout the inner face of the plasma membrane (Figure 2f),
consistent with the altered PI(4,5)P2 localization in post-EMT
cells.48 Membrane-bound ERM proteins still remain poorly
activated even when PIP2 is bound to their N-terminal
domains, but are prone to become robustly activated in
response to LPA stimulation, which triggers their C-terminal
phosphorylation. Eventually, cpERM proteins become
sufﬁciently active to recruit NHERF1 to the plasma membrane.
Our current observations demonstrate the signiﬁcant role of
cpERM proteins not only in static localization of NHERF1 at
the normal epithelium,5,8 but also in active translocation of
NHERF1 in post-EMT cells, suggesting that the cpERM–
NHERF1 complex is preserved both before and after the
EMT, despite the signiﬁcant difference in its physiological
and pathological roles in each context.
In addition to demonstrating cpERM-dependent regulation
of NHERF1 localization, we showed that NHERF1 is a key
regulator of cpERM proteins. NHERF1 depletion signiﬁcantly
Figure 5 NHERF1/cpERM complex is highly enriched at pseudopodia of cells migrating toward a LPA gradient. (a) Localization of cpERM
proteins at the pseudopodia of migrating cells. Schematic representation of pseudopodia formation of cells migrating toward a LPA
gradient (left panel). OVCAR-3 cells were mounted onto collagen-coated 5 μm porous membranes in modiﬁed Boyden chambers, and then
allowed to extend pseudopodia toward the bottom chamber in the absence (aa) or the presence (ab) of LPA (1 μM) for 1 h. In addition, to
conﬁrm pseudopodia formation on the lower surface of the porous membrane, cell bodies on the upper side were cleared with a cotton
swab (ac). Cell preparation is illustrated schematically above each set of images (aa–c). In ﬁxed cells, the nucleus in the cell body and
cpERM in pseudopodia were visualized with PI (propidium iodide) staining and immunostaining with anti-cpERM antibody/Alexa Fluor
488-conjugated secondary antibody, respectively. The plane of focus of confocal microscopy was sequentially adjusted to the top
membrane surface (upper) and then the lower membrane surface (lower) in the same ﬁeld. All results are from a single experiment that
was representative of three experiments performed on independent preparations. Scale bars, 20 μm. (b) CpERM localization at the
protrusion structures at the pseudopodia. Migratory OVCAR-3 cells were prepared as illustrated above each image set. To determine the
subcellular location of cpERM in the migratory cells at the higher resolution (×40 objective), the plane of focus of confocal microscopy
was sequentially adjusted to the upper cell body (Upper), porous membrane (Memb.) and lower pseudopodia (Lower) in a single cell,
as illustrated in the left panel. CpERM proteins are enriched in protrusive structures of the pseudopodia (arrow in ba/b), and to a much
lesser extent in the cell body (arrowhead in ba). Scale bars, 10 μm. (c) Co-localization of NHERF1 with cpERM at pseudopodia of
migrating cells. OVCAR-3 cells transfected with either GFP-NHERF1 or GFP control vector were mounted onto the porous membrane of a
modiﬁed Boyden chamber and prepared as illustrated above each set of images. GFP-NHERF1 and cpERM proteins were visualized in
multiple planes of focus, which were sequentially adjusted to the upper cell body, porous membrane and lower pseudopodia in a single
cell as indicated. CpERM co-localized at the protrusion of the pseudopodia with GFP-NHERF1 (arrows in cb/c), but not with control GFP
(arrowheads in ca). All these results are from a single experiment that was representative of three experiments performed with independent
preparations. Scale bars, 10 μm.
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decreased the cpERM level and abolished cpERM-dependent
cortical reorganization (Figure 3a and b). Presumably,
NHERF1 could inﬂuence the cpERM level through either
potentiation of ERM phosphorylation or stabilization of
cpERMs. It is well established that NHERF1 selectively binds
to cpERMs, but not to non-phospho-ERMs.45,46 Accordingly,
our immunocytochemistry revealed that NHERF1 co-localized
with cpERMs, but not with non-phospho-ERM proteins.
Notably, NHERF1 depletion decreased cpERM levels, but did
not abolish phosphorylation itself (Figures 3a and b, and 4b,).
Moreover, NHERF1 depletion did not inﬂuence other major
phosphorylation events in the AKT, ERK1/2 and SGKα/β
pathways (Figure 3b), suggesting selective regulation of
cpERMs by NHERF1, possibly mediated by direct interactions.
This line of evidence supports the idea that NHERF1 regulates
the stability of cpERMs in a protein complex, rather than
acting upstream of ERM phosphorylation. Consistent with this,
several studies described the rapid dynamics of ERM
phosphorylation.10,49 Estimation of the rate of Ezrin phosphor-
ylation and dephosphorylation using phosphatase and kinase
inhibitors revealed that Ezrin undergoes a phosphocycle of
~ 1–2min in normal epithelial cells. If phosphocycling is
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suppressed by inhibiting dephosphorylation, the polarized
distribution of Ezrin in epithelial cells is lost,3,50 suggesting
that phosphocycling of ERM proteins is constitutive, probably
due to uneven subcellular distribution of kinases, phosphatases
and other regulatory factors such as NHERF1 within
various cellular compartments. In this regard, NHERF1 inter-
action may protect cpERM from phosphatase-dependent
dephosphorylation by masking the phosphosite directly. It is
also plausible that the NHERF1–cpERM complex may isolate
itself inside the cortical protrusion structure, away from the
subcellular region enriched in phosphatases, during cortical
reorganization (Figure 4b). However, we cannot exclude the
possibility that NHERF1 works upstream of ERM phosphor-
ylation. ERM proteins are phosphorylated by several cellular
kinases, including Rho-associated kinase (ROCK),45 myotonic
dystrophy-related Cdc42-binding kinases (MRCK),51 PKC-θ,52
and mammalian STE20-like protein kinase 4 (MST4)53,54 in
epithelial cells, and lymphocyte-oriented kinase (LOK)/STE20-
like kinase (SLK) in lymphocyte and Caco2 cells.50,55 We have
yet to examine the expression patterns of those kinases in
OVCAR-3 cells or the potential inﬂuence of NHERF1
depletion on those kinase activities upon LPA stimulation.
Moreover, cpERM/NHERF1 may recruit several Rho family
GTPase regulators such as RhoGDI and RhoGEF (Dbl) into the
functional complex,7,45 which may provide a positive feedback
loop in the LPA-induced RhoGTPase pathway and ultimately
potentiate ERM phosphorylation. On the other hand, previous
studies have shown that NHERF1 is a substrate for diverse
cellular kinases whose phosphorylation of NHERF1 regulates
its self-oligomerization and protein interactions with other
PDZ ligands.10,56–60 We are not yet able to determine if
NHERF1 is phosphorylated together with other ERM proteins
upon LPA stimulation. If this turns out to be the case, then
NHERF phosphorylation could be engaged in further crosstalk
with ERM phosphorylation, resulting in reciprocal regulation
of their activities. Although the mechanistic regulation model
needs to be further clariﬁed, it is clear that NHERF1 and
cpERM engage in reciprocal regulation within a functional
complex during LPA-triggered signaling events in cancer cells.
The NHERF family of protein has four members.17 Among
them, NHERF1 shares with NHERF2 52% amino-acid identity,
a conserved domain architecture, and common ligands.14
NHERF1 and NHERF2 both have extremely high afﬁnities
for the FERM domain of ERM proteins, and exhibit some
overlap in PDZ ligand speciﬁcity and tissue distributions.61,62
Recent reports highlighted the difference between NHERF1
and NHERF2 in terms of molecular dynamics and subcellular
localizations. NHERF1 displays more active dynamics than
NHERF2 due to subtle differences in its PDZ ligands and
C-terminal ERM-binding domain.63,64 In addition, NHERF1
predominantly localizes in microvilli, whereas NHERF2
localizes in intracellular submicrovilli and vesicular structures.
In this regard, NHERF1 differs signiﬁcantly from NHERF2
regarding its role in regulation of cpERM proteins and
subsequent cortical reorganization (Figures 3a and b, and
4b–d), providing additional evidence that NHERF1 and
NHERF2 play non-redundant roles. NHERF1 co-localizes with
cpERM proteins in protrusion structures of OVCAR-3 ovarian
cancer cells, as also observed in microvilli of normal epithelial
cells. In this regard, distinct molecular interactions of NHERF1
with PDZ ligands and cpERMs may account for the unique
role of NHERF1 in dynamic reorganization of the cell cortex in
ovarian cancer cells.
Molecular dynamics of cytoplasmic NHERF1 and their role
in ovarian cancer progression
Cell polarity is deﬁned as asymmetric distribution of cellular
components and their molecular complexes to particular
regions within cells.65 This asymmetry, especially at the plasma
membrane, is required to establish not only the apical–basal
axis in normal epithelium, but also front–rear polarity in the
mesenchymal cells.1 NHERF1 localizes exclusively underneath
Figure 6 NHERF1 is required for chemotactic migration of cancer cells. (a) Schematic domain structures of GFP-labeled NHERF1
constructs including the wild type (WT), C-terminally truncated form (ΔCT), and C-terminal fragment (CT) (left panel). Expression levels of
GFP-NHERF1 constructs were determined using anti-GFP antibody (right panel) as indicated by the arrows. (b) Inhibition of pseudopodia
formation by overexpression of NHERF1 deletion mutants. OVCAR-3 cells were transfected with GFP-NHERF1 constructs, and migration
assays were performed 2 days after transfection, as described above. The migratory cells ﬁxed on the membrane were probed with
anti-cpERM antibody. Pseudopodial localizations of GFP-NHERF1 and cpERM proteins were imaged under confocal microscopy with
constant settings. These results are from a single experiment that was representative of three experiments performed on independent
preparations. Scale bar, 20 μm. (c) siRNA-mediated silencing of NHERF1 expression in various cell lines derived from gynecological
cancers. OVCAR-3 (ascites-derived ovarian cancer cell line), SK-OV-3 (ascites-derived ovarian cancer cell line) and MDA-MB-231 cells
(breast carcinoma cell line) were tested in this study. Each cell line was transfected with either siRNA duplex speciﬁc for NHERF1 or
control siRNA. NHERF1 levels in cell lysates were determined by western blotting with anti-NHERF1 antibody. (d) Effect of NHERF1
depletion on LPA-induced migration of OVCAR-3 cells. Three days after siRNA transfection, OVCAR-3 cells were mounted onto a
collagen-coated porous membrane (pore size, 8 μm) of a modiﬁed Boyden chamber and allowed to migrate to the lower side for 3.5 h in
the presence or absence of 1 μM LPA in the lower chamber. Migratory cells in the lower membrane were visualized by Hoechst 33342
staining of nuclei. These images from OVCAR-3 cells represent three independent experiments. (e) Effect of NHERF1 depletion on the
migration of gynecological cancer cell lines. OVCAR-3, SK-OV-3 and MDA-MB-231 cells were tested in this study. Each cell line was
transfected with siRNA duplexes as described in (c). After chemotactic migration assays, the membranes were observed by ﬂuorescence
microscopy, and images were captured in ﬁve randomly chosen high-power ﬁelds (HPF, ×20 objective). The numbers of migratory cells per
membrane were directly counted and analyzed statistically in each cell line. Each bar represents the mean± s.e.m. from three independent
experiments. All data represent mean ± s.e.m. *Po0.05 and NS, non-signiﬁcant.
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the apical membrane of normal epithelial layers and serves
as a molecular scaffold to cluster various signaling molecules
into stable complexes.5,8 The restriction of NHERF1
localization is important for microvilli formation on the apical
surface of epithelial cells.8,10 In contrast to normal apical
localization, NHERF1 mainly localizes in the cytoplasm
of invasive carcinoma cells, often concomitant with
overexpression.32,34,36,38–41,66 This relocalization is strongly
associated with cancer progression, metastatic potential,
poor prognosis and estrogen responsiveness, especially in
carcinomas. Furthermore, NHERF1 binds to tumor suppres-
sors, including PTEN and beta-catenin, at the plasma
membrane in normal epithelial cells.39,40,67 These observations
have led to a mechanistic model in which NHERF1 acts as a
tumor suppressor when it is localized at the plasma membrane,
but as a pathogenic protein when it is localized in the
cytoplasm of cancer cells.67 The mechanism underlying the
functional transition of NHERF1 between normal epithelial
cells and the cancer cell remains unknown.
Here we observed that cytoplasmic NHERF1 rapidly trans-
locates to the plasma membrane upon LPA stimulation in
ovarian cancer cells that have lost apical–basal polarity. More
importantly, if the LPA stimulus is given unevenly, NHERF1
translocates asymmetrically to the frontal side, that is, toward
the LPA gradient. This asymmetric membrane translocation of
NHERF1 is crucial for chemotactic cell migration toward a
LPA stimulus. Presumably, in return for the loss of stable apical
localization, NHERF1 gains the freedom to move to any region
on the plasma membrane, and thus the ability to actively reset
the front–rear polarity in post-EMT cells, especially in response
Figure 7 Schematic representation of LPA-induced NHERF1 regulation and its implication for cancer progression. (a) In the resting state,
dormant ERM proteins, which exist as inactive monomers or oligomers, localize primarily to the plasma membrane via interaction with
PIP2. (b) Upon LPA stimulation, ERM proteins are rapidly phosphorylated at the C terminus and undergo a phosphorylation-induced
transition to active monomers at the plasma membrane. (c) NHERF1 is recruited to membrane-anchored cpERM proteins through the
ERM-binding region at the NHERF1 C terminus. (d) The membrane-targeted NHERF1–cpERM complex stabilizes ERM phosphorylation to
play a key role as a molecular scaffold, tethering multiple membranous and cytosolic partners just beneath the plasma membrane, which
leads to the dynamic reorganization of the cell cortex. (e) Human epithelium is composed of cellular monolayers in which individual cells
are tightly linked to their neighbors by tight junctions. In normal epithelium, NHERF1 localizes exclusively in the apical microvilli of the
polarized epithelial cells and plays broad roles ranging from regulation of apical proteins to morphogenesis of the apical membrane itself.
However, during the epithelial–mesenchymal transition (EMT), innately polar cells lose the cell-to-cell junctions that are required for
epithelial integrity and thus lose intrinsic membrane polarity. Eventually, these post-EMT cells behave in an ‘amoeboid’ manner, and are
capable of freely moving in any direction. Here we propose a working model in which cytosolic NHERF1 in cancerous amoeboid cells can
be dynamically redistributed toward extracellular stimuli via interaction with cpERM, and play a key role in the chemotactic cell migration
by resetting the front–rear polarity.
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to extracellular stimuli as exempliﬁed by LPA. Thus, cancer
cells appear to hijack polarity factors, including NHERF1, for
tumor progression by simply redirecting from the apical–basal
polarity of normal epithelium to front–rear polarity in post-
EMT cells. In the current study, we demonstrated that dynamic
relocalization of cytoplasmic NHERF1 mediates the directional
cell migration of ovarian cancer cells toward LPA stimuli. Our
ﬁndings suggest that the high dynamics of cytosolic NHERF1
provide cancer cells with a means of controlling chemotactic
migration, with ensuring maximum plasticity for determining
the moving direction. We believe that our study contributes to
understanding of the pathophysiological role of cytosolic
NHERF1 in cancer cells with no ﬁxed polarity.
Recently emerging evidence indicated that ERM proteins are
closely involved in tumor development.68,69 They are frequently
overexpressed in human tumors derived from breast, ovary,
and rhabdosarcoma, and abnormal distribution of these factors
is correlated with poor prognosis in breast cancer patients.70,71
Ezrin relocalizes from apical membranes in normal epithelium
to the cytoplasm of breast tumors,71 and ERM proteins
promote invasion by tumor cells.69,72 The molecular dynamics
of the cpERM–NHERF1 complex may be associated with
directional cell migration, and with metastasis in cancer. In
this context, our results reveal a novel mechanism by which
cytoplasmic NHERF1 contributes to cancer progression, in
accordance with the pathogenic role of ERM family proteins.
Ovarian cancers are the gynecological malignancies with the
highest case fatality rate,73 ascribed to the fact that the majority
of patients are diagnosed with wide metastasis within the
peritoneal cavity.74 During tumor progression, ovarian cancer
cells metastasize either by directly extending from the epithelial
tumor mass into neighboring organs (bladder/colon) or by
detaching from the primary tumor and disseminating through-
out the peritoneum. Extensive seeding of the ovarian cancer
cells within the peritoneal cavity is associated with ascites,
particularly in the advanced malignancy.74 LPA has been
implicated in ovarian cancer progression30,75 and is highly
enriched in ascites of most patients with malignant ovarian
cancer,22,25–28 and expression of LPAR is aberrantly altered in
ovarian cancer cells,29,76 implicating the LPA/LPAR axis in
poor prognosis of ovarian cancer, especially in cases with
extensive metastasis into nearby tissue or the peritoneum.31,75
In ovarian cancer cells, LPA can strongly stimulate multiple
cellular responses such as cell proliferation, cell migration/
invasion and metastasis.21,22 Nonetheless, the intracellular
mechanism underlying LPA-induced progression of ovarian
cancer has remained unclear. Notably in this regard, our
ﬁndings in this study reveal that the cpERM–NHERF1 complex
is essential for LPA-triggered migration of ascites-derived
OVCAR-3 ovarian cancer cells. In amoeboid cancer cells that
have lost their polarity, NHERF1 displays abnormal intra-
cellular behavior with dynamic shuttling between cytoplasm
and membrane toward the extracellular LPA gradient.
This provides the cancer cells with the ability to engage in
chemotactic migration and metastasis. Considering the patho-
logical signiﬁcance of LPA in ovarian cancer progression,
molecular intervention in the LPA–cpERM–NHERF1 pathway
should be subjected to further in vivo study to determine
whether inhibition of this pathway could be used to prevent or
treat ovarian cancer metastasis.
Now we have to admit that our current study is yet to prove
in vivo relevance of LPA–cpERM–NHERF1 pathway by using
either cancer patient-derived tissue or the xenograft model for
ovarian carcinoma. Practically, it does not seem easy to follow
these phosphorylation-dependent events in human carcinoma
tissues that are generally processed without any speciﬁc
treatment to preserve phospho-proteins and their protein
complexes to truly reﬂect those found at the tumor mass
inside the body. In addition, the various xenograft models have
been developed mainly through the intraperitoneal injection of
ovarian cancer-derived cell lines. Those models have been used
to elucidate molecular events that regulate the ‘terminal
transition’ from free-ﬂoating ascetic cells to metastatic lesions
anchored on the peritonieum.77 Unfortunately, those models
rarely contribute to our understanding of the very earliest
events in the metastasis of ovarian cancers, such as the
migration of tumor cells with metastatic potentials toward
the intraperitoneal cavity and the shedding of cells from the
primary tumor mass.77 In this regard, future studies using
advanced experimental model are warranted to further verify
in vivo relevance of LPA–cpERM–NHERF1 pathway as well as
its pathological importance for the progression of ovarian
cancer.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
We are very grateful to Dr Monique Arpin (CNRS/Institut Curie,
France) for the Ezrin WT and T567 mutant constructs, and also to
Dr Andrew Godwin (Fox Chase Cancer Center, PA) for the HIO-80
cell line. We thank the members of our laboratories for their
contributions and helpful discussions. This work was supported by the
DGIST MIREBraiN R&D program (16-BD-0402 to YSO), Basic
Science Research Program (2016010015, 2014R1A1A1003159 to YSO),
the Korea Brain Research Institute basic research program (2231-415
to YSO) by the Ministry of Science, ICT & Future Planning of Korea,
and the Basic Science Research Program through the National
Research Foundation of Korea (NRF) funded by the Ministry of
Education (2016R1D1A1B03935615 to YSO, 2016R1A6A3A11934335
to JJH). In addition, the National Research Foundation of
Korea (NRF) grant funded by the Korean government (MSIP)
(no 2010-0028684 to PGS) supported this work.
1 Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-
mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15: 178–196.
2 Donowitz M, Cha B, Zachos NC, Brett CL, Sharma A, Tse CM et al. NHERF
family and NHE3 regulation. J Physiol 2005; 567: 3–11.
3 Sauvanet C, Wayt J, Pelaseyed T, Bretscher A. Structure, regulation, and
functional diversity of microvilli on the apical domain of epithelial cells.
Annu Rev Cell Dev Biol 2015; 31: 593–621.
4 Shenolikar S, Weinman EJ. NHERF: targeting and trafﬁcking membrane
proteins. Am J Physiol Renal Physiol 2001; 280: F389–F395.
Role of NHERF1 translocation in LPA-induced cell migration
Y-S Oh et al
15
Experimental & Molecular Medicine
5 Viswanatha R, Bretscher A, Garbett D. Dynamics of ezrin and EBP50 in
regulating microvilli on the apical aspect of epithelial cells. Biochem Soc
Trans 2014; 42: 189–194.
6 Reczek D, Berryman M, Bretscher A. Identiﬁcation of EBP50:
a PDZ-containing phosphoprotein that associates with members of the
ezrin-radixin-moesin family. J Cell Biol 1997; 139: 169–179.
7 Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: the role
of ERM proteins. Nat Rev Mol Cell Biol 2010; 11: 276–287.
8 Morales FC, Takahashi Y, Kreimann EL, Georgescu MM. Ezrin-radixin-
moesin (ERM)-binding phosphoprotein 50 organizes ERM proteins at the
apical membrane of polarized epithelia. Proc Natl Acad Sci USA 2004;
101: 17705–17710.
9 Saotome I, Curto M, McClatchey AI. Ezrin is essential for epithelial
organization and villus morphogenesis in the developing intestine. Dev Cell
2004; 6: 855–864.
10 Garbett D, LaLonde DP, Bretscher A. The scaffolding protein EBP50
regulates microvillar assembly in a phosphorylation-dependent manner.
J Cell Biol 2010; 191: 397–413.
11 Hanono A, Garbett D, Reczek D, Chambers DN, Bretscher A. EPI64
regulates microvillar subdomains and structure. J Cell Biol 2006; 175:
803–813.
12 LaLonde DP, Garbett D, Bretscher A. A regulated complex of the scaffold-
ing proteins PDZK1 and EBP50 with ezrin contribute to microvillar
organization. Mol Biol Cell 2010; 21: 1519–1529.
13 Weinman EJ, Steplock D, Wang Y, Shenolikar S. Characterization of a
protein cofactor that mediates protein kinase A regulation of the renal
brush border membrane Na(+)-H+ exchanger. J Clin Invest 1995; 95:
2143–2149.
14 Yun CH, Oh S, Zizak M, Steplock D, Tsao S, Tse CM et al. cAMP-mediated
inhibition of the epithelial brush border Na+/H+ exchanger, NHE3, requires
an associated regulatory protein. Proc Natl Acad Sci USA 1997; 94:
3010–3015.
15 Seidler U, Singh AK, Cinar A, Chen M, Hillesheim J, Hogema B et al. The
role of the NHERF family of PDZ scaffolding proteins in the regulation of
salt and water transport. Ann NY Acad Sci 2009; 1165: 249–260.
16 Voltz JW, Weinman EJ, Shenolikar S. Expanding the role of NHERF,
a PDZ-domain containing protein adapter, to growth regulation. Oncogene
2001; 20: 6309–6314.
17 Weinman EJ, Hall RA, Friedman PA, Liu-Chen LY, Shenolikar S. The
association of NHERF adaptor proteins with g protein-coupled receptors
and receptor tyrosine kinases. Ann Rev Physiol 2006; 68: 491–505.
18 Oh YS, Jo NW, Choi JW, Kim HS, Seo SW, Kang KO et al. NHERF2
speciﬁcally interacts with LPA2 receptor and deﬁnes the speciﬁcity and
efﬁciency of receptor-mediated phospholipase C-beta3 activation. Mol Cell
Biol 2004; 24: 5069–5079.
19 Bretscher A, Chambers D, Nguyen R, Reczek D. ERM-Merlin and EBP50
protein families in plasma membrane organization and function. Annu Rev
Cell Dev Biol 2000; 16: 113–143.
20 Jung Kang Y, Su Jeon E, Jin Lee H, Oh YS, Suh PG, Sup Jung J et al.
NHERF2 increases platelet-derived growth factor-induced proliferation
through PI-3-kinase/Akt-, ERK-, and Src family kinase-dependent pathway.
Cell Signal 2004; 16: 791–800.
21 Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T et al. LPA
receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol
2010; 50: 157–186.
22 Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid
in cancer. Nat Rev Cancer 2003; 3: 582–591.
23 Mutoh T, Rivera R, Chun J. Insights into the pharmacological relevance of
lysophospholipid receptors. Br J Pharmacol 2012; 165: 829–844.
24 Imamura F, Horai T, Mukai M, Shinkai K, Sawada M, Akedo H. Induction of
in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid
or phospholipase D. Biochem Biophys Res Commun 1993; 193: 497–503.
25 Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A et al.
Characterization of an ovarian cancer activating factor in ascites from
ovarian cancer patients. Clin Cancer Res 1995; 1: 1223–1232.
26 Baker DL, Morrison P, Miller B, Riely CA, Tolley B, Westermann AM et al.
Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA
2002; 287: 3081–3082.
27 Okita M. Abnormal plasma lysophosphatidic acid level in ovarian cancer
patients. Bull Facul Health Welfare Sci 1994; 1: 29–35.
28 Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P et al. Lysophosphatidic
acid as a potential biomarker for ovarian and other gynecologic cancers.
JAMA 1998; 280: 719–723.
29 Jahn SC, Law ME, Corsino PE, Parker NN, Pham K, Davis BJ et al.
An in vivo model of epithelial to mesenchymal transition reveals a
mitogenic switch. Cancer Lett 2012; 326: 183–190.
30 Willier S, Butt E, Grunewald TGP. Lysophosphatidic acid (LPA) signalling in
cell migration and cancer invasion: a focussed review and analysis of LPA
receptor gene expression on the basis of more than 1700 cancer
microarrays. Biol Cell 2013; 105: 317–333.
31 Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT et al.
Lysophosphatidic acid-induced transcriptional proﬁle represents serous
epithelial ovarian carcinoma and worsened prognosis. PLoS ONE 2009; 4:
e5583.
32 Wang L, Du YR, Ji MY, Wang W, Zhan N, Zhou QS et al. Reduced EBP50
expression or mis-localization of the EBP50 protein is associated with the
malignant progression of esophageal squamous cell carcinoma. Eur Rev
Med Pharmacol Sci 2014; 18: 3854–3863.
33 Dai JL, Wang L, Sahin AA, Broemeling LD, Schutte M, Pan Y. NHERF
(Na+/H+ exchanger regulatory factor) gene mutations in human
breast cancer. Oncogene 2004; 23: 8681–8687.
34 Cardone RA, Bellizzi A, Busco G, Weinman EJ, Dell'Aquila ME, Casavola V
et al. The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated
NHE1 activation and invasion in breast tumor cells. Mol Biol Cell 2007;
18: 1768–1780.
35 Schindelmann S, Windisch J, Grundmann R, Kreienberg R, Zeillinger R,
Deissler H. Expression proﬁling of mammary carcinoma cell lines: correla-
tion of in vitro invasiveness with expression of CD24. Tumour Biol 2002;
23: 139–145.
36 Song J, Bai J, Yang W, Gabrielson EW, Chan DW, Zhang Z. Expression and
clinicopathological signiﬁcance of oestrogen-responsive ezrin-radixin-
moesin-binding phosphoprotein 50 in breast cancer. Histopathology
2007; 51: 40–53.
37 Bellizzi A, Greco MR, Rubino R, Paradiso A, Forciniti S, Zeeberg K et al.
The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth,
motility and invadopodia function to geﬁtinib treatment in breast
cancer cells. Int J Oncol 2015; 46: 1214–1224.
38 Hayashi Y, Molina JR, Hamilton SR, Georgescu MM. NHERF1/EBP50 is a
new marker in colorectal cancer. Neoplasia 2010; 12: 1013–1022.
39 Kreimann EL, Morales FC, de Orbeta-Cruz J, Takahashi Y, Adams H, Liu TJ
et al. Cortical stabilization of beta-catenin contributes to NHERF1/EBP50
tumor suppressor function. Oncogene 2007; 26: 5290–5299.
40 Takahashi Y, Morales FC, Kreimann EL, Georgescu MM. PTEN tumor
suppressor associates with NHERF proteins to attenuate PDGF receptor
signaling. EMBO J 2006; 25: 910–920.
41 Saponaro C, Malfettone A, Dell'Endice TS, Brunetti AE, Achimas-Cadariu P,
Paradiso A et al. The prognostic value of the Na(+)/ H(+) exchanger
regulatory factor 1 (NHERF1) protein in cancer. Cancer Biomark 2014; 14:
177–184.
42 Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA.
High-efﬁciency gene transfer and high-level expression of wild-type p53
in human lung cancer cells mediated by recombinant adenovirus. Cancer
Gene Ther 1994; 1: 5–13.
43 Chen HC. Boyden chamber assay. Methods Mol Biol 2005; 294: 15–22.
44 Viswanatha R, Wayt J, Ohouo PY, Smolka MB, Bretscher A. Interactome
analysis reveals ezrin can adopt multiple conformational states. J Biol
Chem 2013; 288: 35437–35451.
45 Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K et al.
Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/
moesin (ERM) proteins and regulates their head-to-tail association. J Cell
Biol 1998; 140: 647–657.
46 Fievet BT, Gautreau A, Roy C, Del Maestro L, Mangeat P, Louvard D et al.
Phosphoinositide binding and phosphorylation act sequentially in the
activation mechanism of ezrin. J Cell Biol 2004; 164: 653–659.
47 Nabi IR. The polarization of the motile cell. J Cell Sci 1999; 112(Pt 12):
1803–1811.
48 Shewan A, Eastburn DJ, Mostov K. Phosphoinositides in cell architecture.
Cold Spring Harbor Perspect Biol 2011; 3: a004796.
49 Coscoy S, Waharte F, Gautreau A, Martin M, Louvard D, Mangeat P et al.
Molecular analysis of microscopic ezrin dynamics by two-photon FRAP.
Proc Natl Acad Sci USA 2002; 99: 12813–12818.
50 Viswanatha R, Ohouo PY, Smolka MB, Bretscher A. Local phosphocycling
mediated by LOK/SLK restricts ezrin function to the apical aspect of
epithelial cells. J Cell Biol 2012; 199: 969–984.
51 Nakamura N, Oshiro N, Fukata Y, Amano M, Fukata M, Kuroda S et al.
Phosphorylation of ERM proteins at ﬁlopodia induced by Cdc42. Genes
Cells 2000; 5: 571–581.
Role of NHERF1 translocation in LPA-induced cell migration
Y-S Oh et al
16
Experimental & Molecular Medicine
52 Pietromonaco SF, Simons PC, Altman A, Elias L. Protein kinase C-theta
phosphorylation of moesin in the actin-binding sequence. J Biol Chem
1998; 273: 7594–7603.
53 Gloerich M, ten Klooster JP, Vliem MJ, Koorman T, Zwartkruis FJ, Clevers H
et al. Rap2A links intestinal cell polarity to brush border formation. Nat Cell
Biol 2012; 14: 793–801.
54 ten Klooster JP, Jansen M, Yuan J, Oorschot V, Begthel H, Di Giacomo V
et al. Mst4 and Ezrin induce brush borders downstream of the Lkb1/Strad/
Mo25 polarization complex. Dev Cell 2009; 16: 551–562.
55 Belkina NV, Liu Y, Hao JJ, Karasuyama H, Shaw S. LOK is a major ERM
kinase in resting lymphocytes and regulates cytoskeletal rearrangement
through ERM phosphorylation. Proc Natl Acad Sci USA 2009; 106:
4707–4712.
56 He J, Lau AG, Yaffe MB, Hall RA. Phosphorylation and cell cycle-
dependent regulation of Na+/H+ exchanger regulatory factor-1 by
Cdc2 kinase. J Biol Chem 2001; 276: 41559–41565.
57 Lau AG, Hall RA. Oligomerization of NHERF-1 and NHERF-2 PDZ
domains: differential regulation by association with receptor carboxyl-
termini and by phosphorylation. Biochemistry 2001; 40: 8572–8580.
58 Weinman EJ, Steplock D, Zhang Y, Biswas R, Bloch RJ, Shenolikar S.
Cooperativity between the phosphorylation of Thr95 and Ser77 of NHERF-1
in the hormonal regulation of renal phosphate transport. J Biol Chem 2010;
285: 25134–25138.
59 Voltz JW, Brush M, Sikes S, Steplock D, Weinman EJ, Shenolikar S.
Phosphorylation of PDZ1 domain attenuates NHERF-1 binding to cellular
targets. J Biol Chem 2007; 282: 33879–33887.
60 Fouassier L, Nichols MT, Gidey E, McWilliams RR, Robin H, Finnigan C
et al. Protein kinase C regulates the phosphorylation and oligomerization of
ERM binding phosphoprotein 50. Exp Cell Res 2005; 306: 264–273.
61 Shenolikar S, Voltz JW, Cunningham R, Weinman EJ. Regulation of ion
transport by the NHERF family of PDZ proteins. Physiology 2004; 19:
362–369.
62 Terawaki S, Maesaki R, Hakoshima T. Structural basis for NHERF
recognition by ERM proteins. Structure 2006; 14: 777–789.
63 Garbett D, Bretscher A. PDZ interactions regulate rapid turnover of the
scaffolding protein EBP50 in microvilli. J Cell Biol 2012; 198: 195–203.
64 Garbett D, Sauvanet C, Viswanatha R, Bretscher A. The tails of apical
scaffolding proteins EBP50 and E3KARP regulate their localization and
dynamics. Mol Biol Cell 2013; 24: 3381–3392.
65 Mullin JM. Epithelial barriers, compartmentation, and cancer. Sci STKE
2004; 2004: pe2.
66 Shibata T, Chuma M, Kokubu A, Sakamoto M, Hirohashi S. EBP50, a beta-
catenin-associating protein, enhances Wnt signaling and is over-expressed
in hepatocellular carcinoma. Hepatology 2003; 38: 178–186.
67 Georgescu MM, Morales FC, Molina JR, Hayashi Y. Roles of
NHERF1/EBP50 in cancer. Curr Mol Med 2008; 8: 459–468.
68 McClatchey AI. Merlin and ERM proteins: unappreciated roles in cancer
development? Nat Rev Cancer 2003; 3: 877–883.
69 Clucas J, Valderrama F. ERM proteins in cancer progression. J Cell Sci
2015; 128: 1253.
70 Bruce B, Khanna G, Ren L, Landberg G, Jirstrom K, Powell C et al.
Expression of the cytoskeleton linker protein ezrin in human cancers. Clin
Exp Metastasis 2007; 24: 69–78.
71 Sarrio D, Rodriguez-Pinilla SM, Dotor A, Calero F, Hardisson D, Palacios J.
Abnormal ezrin localization is associated with clinicopathological features
in invasive breast carcinomas. Breast Cancer Res Treat 2006; 98: 71–79.
72 Li Q, Gao H, Xu H, Wang X, Pan Y, Hao F et al. Expression of ezrin
correlates with malignant phenotype of lung cancer, and in vitro knockdown
of ezrin reverses the aggressive biological behavior of lung cancer cells.
Tumour Biol 2012; 33: 1493–1504.
73 Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009.
CA Cancer J Clin 2009; 59: 225–249.
74 Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010;
177: 1053–1064.
75 Jesionowska A, Cecerska-Heryc E, Matoszka N, Dolegowska B.
Lysophosphatidic acid signaling in ovarian cancer. J Recept Signal
Transduct Res 2015; 35: 578–584.
76 Murph MM, Nguyen GH, Radhakrishna H, Mills GB. Sharpening the edges
of understanding the structure/function of the LPA1 receptor: expression in
cancer and mechanisms of regulation. Biochim Biophys Acta 2008; 1781:
547–557.
77 Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P et al.
Epithelial ovarian cancer experimental models. Oncogene 2014; 33:
3619–3633.
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivs 4.0 Inter-
national License. The images or other third party material in
this article are included in the article’s Creative Commons
license, unless indicated otherwise in the credit line; if the
material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to
reproduce the material. To view a copy of this license, visit
http://creativecommons.org/licenses/by-nc-nd/4.0/
Supplementary Information accompanies the paper on Experimental & Molecular Medicine website (http://www.nature.com/emm)
Role of NHERF1 translocation in LPA-induced cell migration
Y-S Oh et al
17
Experimental & Molecular Medicine
